2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents

Journal of the American College of Cardiology

Volumn 69, Issue 2, 2017, Pages 162-171

  Garot, Philippe ^a,b   Morice, Marie Claude ^b,v   Tresukosol, Damras ^c   Pocock, Stuart J ^d,v   Meredith, Ian T ^e,v   Abizaid, Alexandre ^f   Carrié, Didier ^g,v   Naber, Christoph ^h,v   Iñiguez, Andres ⁱ   Talwar, Suneel ^j   Menown, Ian B A ^k   Christiansen, Evald H ^l   Gregson, John ^d   Copt, Samuel ^m   Hovasse, Thomas ^b   Lurz, Philipp ⁿ   Maillard, Luc ^o   Krackhardt, Florian ^p   Ong, Paul ^q   Byrne, Jonathan ^r   Redwood, Simon ^s   Windhövel, Ute ^t   Greene, Samantha ^m,v   Stoll, Hans Peter ^m,v   Urban, Philip ^u,v   Abizaid, Alexander ^v   more..

^a Institut Cardiovasculaire Paris sud Ramsay Générale de Santé   (France)

^b INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^c MAHIDOL UNIVERSITY   (Thailand)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e MONASH UNIVERSITY   (Australia)

^f HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^g CHU RANGUEIL   (France)

^h ELISABETH KRANKENHAUS ESSEN   (Germany)

ⁱ UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^j ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^k Craigavon Cardiac Center   (United Kingdom)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m Biosensors Europe SA   (Switzerland)

ⁿ UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^o Groupement de Coopération Sanitaire Etablissements de Santé   (France)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q TAN TOCK SENG HOSPITAL   (Singapore)

^r KING S COLLEGE HOSPITAL   (United Kingdom)

^s ST THOMAS HOSPITAL   (United Kingdom)

^t European Cardiovascular Research Center   (France)

^u LA TOUR HOSPITAL   (Switzerland)

^v NONE

more..

Author keywords

bare metal stent; bleeding; drug coated stent; dual antiplatelet therapy; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; VITAMIN K GROUP; ANTITHROMBOCYTIC AGENT; RAPAMYCIN; UMIROLIMUS;

AGED; ANEMIA; ANTICOAGULATION; ARTICLE; BARE METAL STENT; BIOLIMUS ELUTING CORONARY STENT; BLEEDING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEVICE SAFETY; DOUBLE BLIND PROCEDURE; HEART DEATH; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TREATMENT OUTCOME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CORONARY DISEASE; CORONARY THROMBOSIS; DEATH; DEVICES; DRUG ELUTING STENT; FEMALE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICS; STENT; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CORONARY DISEASE; CORONARY THROMBOSIS; DEATH; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SIROLIMUS; STATISTICS AS TOPIC; STENTS; SURVIVAL RATE;

EID: 85008703775     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.10.009     Document Type: Article

References (40)

1. 1 Urban, P., Meredith, I.T., Abizaid, A., et al., for the LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373 (2015), 2038–2047.
2. 2 Ariotti, S., Adamo, M., Costa, F., et al., for the ZEUS Investigators. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS trial. J Am Coll Cardiol Intv 9 (2016), 426–436.
3. 3 Stone, G.W., Rizvi, A., Newman, W., et al., for the SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362 (2010), 1663–1674.
4. 4 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
5. 5 Kim, B.K., Hong, M.K., Shin, D.H., et al., for the RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
6. 6 Feres, F., Costa, R.A., Abizaid, A., et al., for the OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
7. 7 Levine, G.N., Bates, E.R., Bittl, J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
8. 8 Windecker, S., Kohl, P., Alfonso, F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
9. 9 Tada, N., Virmani, R., Grant, G., et al. Polymer-free biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv 3 (2010), 174–183.
10. 10 Costa, R.A., Abizaid, A., Mehran, R., et al., for the BioFreedom FIM Clinical Trial Investigators. Polymer-free biolimus A9-coated stents in the treatment of de novo coronary lesions: 4- and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective, multicenter BioFreedom FIM clinical trial. J Am Coll Cardiol Intv 9 (2016), 51–64.
11. 11 Urban, P., Abizaid, A., Chevalier, B., et al. Rationale and design of the LEADERS FREE trial: a randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J 165 (2013), 704–709.
12. 12 Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
13. 13 Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. Circulation 126 (2012), 2020–2035.
14. 14 Cutlip, D.E., Windecker, S., Mehran, R., et al., for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
15. 15 Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
16. 16 Rubin, D.B., Inference and missing data. Biometrika 63 (1976), 581–592.
17. 17 Mehran, R., Pocock, S.J., Stone, G.W., et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30 (2009), 1457–1466.
18. 18 Byrne, R.A., Iijima, R., Mehilli, J., et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol Intv 2 (2009), 291–299.
19. 19 Byrne, R.A., Kastrati, A., Tiroch, K., et al., for the ISAR-TEST-2 Investigators. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol 55 (2010), 2536–2543.
20. 20 Räber, L., Wohlwend, L., Wigger, M., et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 123 (2011), 2819–2828.
21. 21 Jensen, L.O., Thayssen, P., Christiansen, E.H., et al., for the SORT OUT IV Investigators. Safety and efficacy of everolimus- versus sirolimus-eluting stents: 5-year results from SORT OUT IV. J Am Coll Cardiol 67 (2016), 751–762.
22. 22 Serruys, P.W., Silber, S., Garg, S., et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 363 (2010), 136–146.
23. 23 Serruys, P.W., Farooq, V., Kalesan, B., et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. J Am Coll Cardiol Intv 6 (2013), 777–789.
24. 24 Sen, H., Lam, M.K., Löwik, M.M., et al. Clinical events and patient-reported chest pain in all-comers treated with Resolute integrity and Promus element stents: 2-year follow-up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II). J Am Coll Cardiol Intv 8 (2015), 889–899.
25. 25 Kaiser, C., Galatius, S., Jeger, R., et al., for the BASKET-PROVE II Study Group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kostent-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 131 (2015), 74–81.
26. 26 Räber, L., Kelbaek, H., Taniwaki, M., et al., for the COMFORTABLE AMI Trial Investigators. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circ Cardiovasc Interv 7 (2014), 355–364.
27. 27 Tandjung, K., Sen, H., Lam, M.K., et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 61 (2013), 2406–2416.
28. 28 Kaiser, C., Galatius, S., Erne, P., et al., for the BASKET-PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 363 (2010), 2310–2319.
29. 29 Kappetein, A.P., Feldman, T.E., Mack, M.J., et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 32 (2011), 2125–2134.
30. 30 Valgimigli, M., Patialiakas, A., Thury, A., et al., for the ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 65 (2015), 805–815.
31. 31 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al., for the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
32. 32 Bønaa, K.H., Mannsverk, J., Wiseth, R., et al., for the NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 375 (2016), 1242–1252.
33. 33 Silber, S., Kirtane, A.J., Belardi, J.A., et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 35 (2014), 1949–1956.
34. 34 Baber, U., Mehran, R., Giustino, G., et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67 (2016), 2224–2234.
35. 35 Généreux, P., Giustino, G., Witzenbichler, B., et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 66 (2015), 1036–1045.
36. 36 Stone, G.W., Witzenbichler, B., Weisz, G., et al., for the ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicenter registry study. Lancet 382 (2013), 614–623.
37. 37 Baber, U., Dangas, G., Chandrasekhar, J., et al. Time-dependent associations between actionable bleeding, coronary thrombotic events, and mortality following percutaneous coronary intervention: results from the PARIS Registry. J Am Coll Cardiol Intv 9 (2016), 1349–1357.
38. 38 Pilgrim, T., Vetterli, F., Kalesan, B., et al. The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. Circ Cardiovasc Interv 5 (2012), 202–210.
39. 39 Mehran, R., Pocock, S.J., Nikolsky, E., et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 55 (2010), 2556–2566.
40. 40 Rubboli, A., Kovacic, J.C., Mehran, R., Lip, G.Y., Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options. Chest 139 (2011), 981–987.